Csl's Latest Blow Supports Continued Caution

Dow Jones

Jun 30

2356 GMT - The almost certain withdrawal of the CSL-marketed Tavneos therapy in Europe only adds to Macquarie's caution toward the Australian biotechnology company. An analyst at the investment bank tells clients in a note that a European Commission ruling on the treatment appears to be a formality, and trims EPS forecasts by 3% for fiscal 2027 and by 4% for fiscal 2028. The analyst reiterates a neutral rating on the stock and reminds readers of the significant near-term earnings uncertainty across CSL's core business segments, plus ongoing medium-term competitive risks. Target price rises 2.7% to 114.00 Australian dollars, reflecting currency moves. Shares are at A$115.39 ahead of the open. (stuart.condie@wsj.com)

(END) Dow Jones Newswires

June 29, 2026 19:56 ET (23:56 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/2647588908"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2647588908\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2647588908?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-30 07:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2647588908","market":"us","top_or_hot":-1,"title":"Csl's Latest Blow Supports Continued Caution","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     2356 GMT - The almost certain withdrawal of the CSL-marketed Tavneos therapy in Europe only adds to <a href=\"https://laohu8.com/S/MQG.AU\">Macquarie</a>'s caution toward the Australian biotechnology company. An analyst at the investment bank tells clients in a note that a European Commission ruling on the treatment appears to be a formality, and trims EPS forecasts by 3% for fiscal 2027 and by 4% for fiscal 2028. The analyst reiterates a neutral rating on the stock and reminds readers of the significant near-term earnings uncertainty across CSL's core business segments, plus ongoing medium-term competitive risks. Target price rises 2.7% to 114.00 Australian dollars, reflecting currency moves. Shares are at A$115.39 ahead of the open. (stuart.condie@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 29, 2026 19:56 ET (23:56 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Csl's Latest Blow Supports Continued Caution</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCsl's Latest Blow Supports Continued Caution\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-06-30 07:56</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     2356 GMT - The almost certain withdrawal of the CSL-marketed Tavneos therapy in Europe only adds to <a href=\"https://laohu8.com/S/MQG.AU\">Macquarie</a>'s caution toward the Australian biotechnology company. An analyst at the investment bank tells clients in a note that a European Commission ruling on the treatment appears to be a formality, and trims EPS forecasts by 3% for fiscal 2027 and by 4% for fiscal 2028. The analyst reiterates a neutral rating on the stock and reminds readers of the significant near-term earnings uncertainty across CSL's core business segments, plus ongoing medium-term competitive risks. Target price rises 2.7% to 114.00 Australian dollars, reflecting currency moves. Shares are at A$115.39 ahead of the open. (stuart.condie@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 29, 2026 19:56 ET (23:56 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7501","symbol_name":"新冠治疗股","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2647588908","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2647588908","pubTimestamp":1782777360,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"2356 GMT - The almost certain withdrawal of the CSL-marketed Tavneos therapy in Europe only adds to Macquarie's caution toward the Australian biotechnology company. An analyst at the investment bank tells clients in a note that a European Commission ruling on the treatment appears to be a formality, and trims EPS forecasts by 3% for fiscal 2027 and by 4% for fiscal 2028. The analyst reiterates a neutral rating on the stock and reminds readers of the significant near-term earnings uncertainty across CSL's core business segments, plus ongoing medium-term competitive risks. Target price rises 2.7% to 114.00 Australian dollars, reflecting currency moves. Shares are at A$115.39 ahead of the open.  Dow Jones NewswiresJune 29, 2026 19:56 ET Copyright  2026 Dow Jones & Company, Inc.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7501":"新冠治疗股","BK7511":"ESG概念","CSL.AU":"CSL LIMITED","BK7067":"生物科技","BK7508":"医药生物股"},"translate_title":"Csl的最新打击支持持续谨慎","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CSL.AU":0.9},"content_text":"2356 GMT - The almost certain withdrawal of the CSL-marketed Tavneos therapy in Europe only adds to Macquarie's caution toward the Australian biotechnology company. An analyst at the investment bank tells clients in a note that a European Commission ruling on the treatment appears to be a formality, and trims EPS forecasts by 3% for fiscal 2027 and by 4% for fiscal 2028. The analyst reiterates a neutral rating on the stock and reminds readers of the significant near-term earnings uncertainty across CSL's core business segments, plus ongoing medium-term competitive risks. Target price rises 2.7% to 114.00 Australian dollars, reflecting currency moves. Shares are at A$115.39 ahead of the open. (stuart.condie@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 29, 2026 19:56 ET (23:56 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}